List of clinical studies of hormonal birth control
The following is a list of notable clinical studies of hormonal birth control in premenopausal women:[1]
- Royal College of General Practitioners Oral Contraception Study[1][2]
- Oxford/Family Planning Association Contraceptive Study (Oxford–FPA Study)[1][3]
- Kaiser Permanente Walnut Creek Contraceptive Drug Study (CDS)[1][4][5]
- World Health Organization Special Programme on Human Reproduction (HRP)[6][7][8]
- Oral Contraceptive and Hemostasis Study Group[9][10][11]
- International Active Surveillance Study – Safety of Contraceptives: Role of Estrogens (INAS-SCORE)[12][13][14]
- Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17β-Estradiol (1.5mg) (PRO-E2)[15][13][14]
See also[edit]
References[edit]
- ^ a b c d Rosenfield A (May 1982). "The pill: an evaluation of recent studies". Johns Hopkins Med J. 150 (5): 177–80. PMID 7043036.
- ^ Grant EC, Robinson J (May 1981). "The R.C.G.P. oral contraception study". Lancet. 1 (8231): 1206–7. doi:10.1016/s0140-6736(81)92366-7. PMID 6112543. S2CID 20271773.
- ^ Vessey MP, Lawless M (December 1984). "The Oxford-Family Planning Association contraceptive study". Clinics in Obstetrics and Gynaecology. 11 (3): 743–57. doi:10.1016/S0306-3356(21)00625-7. PMID 6509857.
- ^ Ramcharan S, Pellegrin FA, Ray RM, Hsu JP (December 1980). "The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Volume III, an interim report: A comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives". J Reprod Med. 25 (6 Suppl): 345–72. PMID 7205804.
- ^ Savitri Ramcharan, ed. (1974). Walnut Creek Contraceptive Drug Study: A Prospective Study of the Side Effects of Oral Contraceptives, Volume 3. National Institute of Child Health and Human Development, Center for Population Research. OCLC 1279046.
- ^ Benagiano, G., & Merialdi, M. (2011). Carl Djerassi and the World Health Organisation special programme of research in human reproduction. Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology, 8(1), 10-13. http://www.kup.at/kup/pdf/10163.pdf
- ^ Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
- ^ Koetsawang S (1991). "The injectable contraceptive: present and future trends". Ann. N. Y. Acad. Sci. 626 (1): 30–42. Bibcode:1991NYASA.626...30K. doi:10.1111/j.1749-6632.1991.tb37897.x. PMID 1829341. S2CID 27008012.
- ^ Oral Contraceptive Hemostasis Study Group (March 2003). "The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study". Contraception. 67 (3): 173–85. doi:10.1016/s0010-7824(02)00476-6. PMID 12618251.
- ^ "An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. Outline of the protocol. Oral Contraceptive and Hemostasis Study Group". Contraception. 59 (6): 345–55. June 1999. doi:10.1016/s0010-7824(99)00044-x. PMID 10518228.
- ^ Hugon-Rodin J, Gompel A, Plu-Bureau G (December 2014). "Epidemiology of hormonal contraceptives-related venous thromboembolism". Eur J Endocrinol. 171 (6): R221–30. doi:10.1530/EJE-14-0527. PMID 25012200.
- ^ Dinger J, Do Minh T, Heinemann K (October 2016). "Impact of estrogen type on cardiovascular safety of combined oral contraceptives". Contraception. 94 (4): 328–39. doi:10.1016/j.contraception.2016.06.010. PMID 27343748.
- ^ a b Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J (2021). "Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk". Front Endocrinol (Lausanne). 12: 769187. doi:10.3389/fendo.2021.769187. PMC 8697849. PMID 34956081.
- ^ a b Grandi G, Facchinetti F, Bitzer J (February 2022). "Confirmation of the safety of combined oral contraceptives containing oestradiol on the risk of venous thromboembolism". Eur J Contracept Reprod Health Care. 27 (2): 83–84. doi:10.1080/13625187.2022.2029397. PMID 35133236. S2CID 246651102.
- ^ Reed S, Koro C, DiBello J, Becker K, Bauerfeind A, Franke C, Heinemann K (December 2021). "Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism". Eur J Contracept Reprod Health Care. 26 (6): 439–446. doi:10.1080/13625187.2021.1987410. PMID 34644228. S2CID 238858357.